Paysign Business Summary

Paysign, Inc. (PAYS) operates as a vertically integrated fintech provider specializing in prepaid card programs and customized payment processing for the healthcare and life sciences industries. The company generates revenue through a diverse mix of transaction-based fees—including interchange, cardholder maintenance, and ATM fees—alongside recurring program management fees, settlement income, and transaction claims processing fees. Its business is primarily segmented into plasma donor compensation, which serves the unbanked donor population, and its high-growth pharmaceutical patient affordability division, which provides co-pay assistance and medical reimbursement solutions. Paysign competes directly with established fintech and healthcare service players such as Green Dot, Block (Square), CoreCard, and GoodRx, positioning itself as a specialized niche leader that leverages a proprietary full-stack platform to offer more transparent and efficient pricing than traditional legacy processors. The company was co-founded by Mark Newcomer and Daniel Spence, with Newcomer currently serving as President and Chief Executive Officer, bringing over two decades of leadership in the payments sector. The executive team is further bolstered by Chief Financial Officer Jeffery Baker, a veteran of payment industry M&A, and Chief Operating Officer Cosimo Cambi, who previously led operational scaling in the patient affordability space. Technology initiatives are directed by CTO Brad Cunningham, formerly of Republic Bank & Trust, where he modernized core banking architectures. A significant governance milestone occurred in August 2025 with the election of Dan Henry—the former CEO of Green Dot and NetSpend—as Chairman of the Board, joining other notable directors such as Matthew Lanford and Joan Herman to provide deep institutional expertise in global payment systems.